Roivant Sciences operates as a biopharmaceutical company, developing novel therapies for diseases with significant unmet needs. The company's distinct business model involves creating "Vants," or ...

Roivant Sciences has a twelve month low of $9.76 and a twelve month high of $13.06. Several research firms have recently weighed in on ROIV. HC Wainwright reissued a “buy” rating and issued a ...

Roivant Sciences (NASDAQ:ROIV – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a report issued on Tuesday,Benzinga reports. They currently have a ...

Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on ROIV: Roivant Sciences NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

Ladies and gentlemen, thank you for standing by. Welcome to Roivant Second Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode. After the speaker's presentation ...

Roivant Sciences showcased an active quarter marked by significant pipeline developments, including a new cutaneous sarcoidosis trial for brepocitinib and upcoming MG and CIDP data for its anti ...

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at ...

Roivant Sciences beat estimated earnings by 17.0%, reporting an EPS of $-0.2 versus an estimate of $-0.24. Revenue was down $28.12 million from the same period last year. The company beat on EPS ...

Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on ROIV: Roivant Sciences NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.21 per share a year ago.